While the identification and diagnosis of congenital disorders of glycosylation (CDG) have rapidly progressed, the available treatment options are still quite limited. Mostly, we are only able to manage the disease symptoms rather than to address the underlying cause. However, recent years have brought about remarkable advances in treatment approaches for some CDG. Innovative therapies, targeting both the root cause and resulting manifestations, have transitioned from the research stage to practical application. The present paper aims to provide a detailed overview of these exciting developments and the rising concepts that are used to treat these ultra-rare diseases.
Keywords: Chaperones; Congenital disorders of glycosylation; Drug repurposing; Epalrestat; GLM101; Monosaccharide.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.